BGMS: Rentang target analis Cyclacel Pharmaceuticals

Bio Green Med Solution Inc (BGMS) develops targeted cell cycle inhibitors, leveraging a robust patent portfolio and a debt-free balance sheet. The company maintains its human capital by attracting experts in translational medicine. This chart reflects current share prices fixed at 239.48. The efficiency of new drug synthesis is driven by the implementation of robotics, eliminating the need to expand laboratory staff during production scaling.

This indicator represents the weighted average of target prices from leading analysts, reflecting the asset's fundamental value over a one-year horizon. The consolidated target valuation from investment banks for Bio Green Med Solution Inc (BGMS) confirms the business's investment attractiveness, as patent protection in the US and the absence of sanction risks in the oncotherapy sector stabilize expert forecasts.